Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Organon
OGN
Organon
Rising Women's Health Demand And Telemedicine Will Fuel Global Access
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
01 Jun 25
Updated
15 Aug 25
3
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
US$18.00
48.6% undervalued
intrinsic discount
15 Aug
US$9.26
Loading
1Y
-55.5%
7D
2.3%
Author's Valuation
US$18.0
48.6% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
US$18.0
48.6% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
11b
2017
2019
2021
2023
2025
2027
2028
Revenue US$6.6b
Earnings US$1.0b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
1.08%
Pharma revenue growth rate
0.57%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
9.68%
Calculation
US$1.03b
Earnings '28
x
6.14x
PE Ratio '28
=
US$6.34b
Market Cap '28
US$6.34b
Market Cap '28
/
267.59m
No. shares '28
=
US$23.68
Share Price '28
US$23.68
Share Price '28
Discounted to 2025 @ 9.65% p.a.
=
US$17.96
Fair Value '25